Brimonidine purite solution for open-angle glaucoma or ocular hypertension

被引：0
|
作者：
Batiste, Corey G. [2 ,3 ]
Myers, Jonathan [2 ,3 ]
Katz, L. Jay [1 ,3 ]
机构：
[1] Wills Eye Hosp & Res Inst, Glaucoma Serv, Philadelphia, PA 19107 USA
[2] Wills Eye Hosp & Res Inst, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Med Univ, Philadelphia, PA 19107 USA
来源：
EXPERT REVIEW OF OPHTHALMOLOGY | 2008年 / 3卷 / 05期
关键词：
brimonidine purite; ocular hypertension; open-angle glaucoma;
D O I：
10.1586/17469899.3.5.513
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Brimonidine (0.1 and 0.15%) tartrate used with the preservative purite has been shown to be as efficacious as brimonidine 0.2% tartrate in lowering intraocular pressure in clinical trials. The purite preservative has proven to be better tolerated and less toxic in brimonidine solution than the original preservative benzalkonium chloride. In addition, the lower concentrations of active drug appear to offer safer adverse event profiles than the original formulation, while maintaining its efficacy.
引用
收藏
页码：513 / 515
页数：3
相关论文
共 50 条
  • [41] Pulsatile ocular blood flow in primary open-angle glaucoma and ocular hypertension
    Kerr, A
    Nelson, P
    O'brien, C
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (06) : 1106 - 1113
  • [42] Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension
    Cengiz Akarsu
    Sevda Yılmaz
    Pelin Taner
    Ahmet Ergin
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2004, 242 : 814 - 818
  • [43] Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension
    Akarsu, C
    Yilmaz, S
    Taner, P
    Ergin, A
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2004, 242 (10) : 814 - 818
  • [44] The effectiveness and safety of brimonidine as replacement therapy for patients with primary open-angle hypertension or ocular hypertension
    Lee, DA
    Gornbein, J
    Trovati, V
    Abrams, C
    York, J
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S514 - S514
  • [45] An economic analysis of switching to latanoprost from a β-blocker or adding brimonidine or latanoprost to a β-blocker in open-angle glaucoma or ocular hypertension
    Stewart, WC
    Leech, J
    Sharpe, ED
    Kulze, J
    Ellyn, J
    Day, DG
    AMERICAN JOURNAL OF MANAGED CARE, 2002, 8 (10): : S240 - S248
  • [46] Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension
    Topouzis, Fotis
    Goldberg, Ivan
    Bell, Katharina
    Tatham, Andrew J.
    Ridolfi, Antonia
    Hubatsch, Douglas
    Nicolela, Marcelo
    Denis, Phillipe
    Fabian Lerner, S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (01) : 103 - 111
  • [47] Open-angle glaucoma and ocular perfusion
    Konstas, Anastasios G. P.
    Mikropoulos, Dimitrios G.
    Irkec, Murat
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (10) : 1273 - 1274
  • [48] Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension
    Sharpe, ED
    Day, DG
    Beischel, CJ
    Rhodes, JS
    Stewart, JA
    Stewart, WC
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (07) : 953 - 956
  • [49] Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension
    Kim, Chan Yun
    Hong, Samin
    Seong, Gong Je
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2007, 23 (05) : 481 - 486
  • [50] Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
    Aref, Ahmad A.
    Geyman, Lawrence S.
    Zakieh, Abdel-Rahman
    Alotaibi, Humoud M.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (12) : 1073 - 1079
12345